GET DAILY SIGNALSSilo Pharma (SILO): Following the Pipeline for CNS and PTSD Therapies
Key Takeaways
- Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on central nervous system (CNS) conditions, including PTSD, anxiety disorders, fibromyalgia, and multiple sclerosis.
- The company's lead program, SPC-15, is an intranasal therapeutic candidate targeting post-traumatic stress disorder (PTSD) and stress-induced anxiety disorders.
- SILO develops both conventional drugs and psychedelic-based formulations, including ketamine and psilocybin-based approaches.
- As a development-stage business, Silo Pharma generates minimal revenue and has reported net losses, which is typical for early-stage drug developers.
- Investors follow SILO primarily for its clinical pipeline and potential future regulatory milestones rather than current earnings.
Getting Started with Silo Pharma
SILO is a development-stage biopharmaceutical company traded on the Nasdaq Capital Market. The company is working to develop novel therapeutics for underserved conditions affecting the central nervous system (CNS), including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and neurological diseases. As an early-stage drug developer with a pipeline still in preclinical and early clinical stages, Silo Pharma has not yet commercialized a product and generates little to no revenue. Investors who follow the ticker are generally focused on the long-term potential of its drug candidates and any progress toward regulatory approval.
Background and Corporate Evolution
Silo Pharma was incorporated in the state of New York on July 13, 2010. The company subsequently reincorporated in Delaware in 2013 and, in December 2023, changed its state of incorporation to Nevada. Its principal executive offices are located in Sarasota, Florida. The company operates as a small organization, consistent with its development-stage status.
The company's business model centers on identifying, licensing, and advancing therapeutic assets that address unmet medical needs, with a particular emphasis on treatments for mental health conditions and neurological disorders. Silo Pharma has stated that it seeks to acquire and develop intellectual property and technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs such as psilocybin and ketamine for depression, mental health issues, and neurological disorders. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Pipeline Overview
Silo Pharma's financial profile and market position are tied closely to its investigational pipeline rather than to marketed products. The company's lead program, SPC-15, is an intranasal prophylactic being developed for PTSD and stress-induced anxiety disorders. The company has described plans to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin clinical testing.
Beyond SPC-15, the company's pipeline includes:
- SP-26, a time-release, ketamine-based implant being developed for fibromyalgia and chronic pain relief.
- SPC-14, a preclinical intranasal compound targeting Alzheimer's disease.
- SPU-16, a CNS-homing peptide targeting the central nervous system, with an initial research indication in multiple sclerosis (MS).
Because these candidates are largely in preclinical or early clinical stages, the company's primary revenue sources are minimal, consisting of limited licensing revenue. It relies on equity financing and other capital-raising activities to fund its research and operations.
Why the Ticker Draws Attention
Investor interest in Silo Pharma is driven primarily by the long-term potential of its pipeline, particularly its focus on PTSD and other mental health conditions where existing treatment options can be limited. The company's emphasis on psychedelic and alternative drug formulations positions it within an emerging segment of biopharmaceutical research that has drawn growing scientific and commercial attention.
The company's intranasal delivery approach for SPC-15 and its ketamine-based implant for SP-26 represent differentiated mechanisms that could, if successfully developed and approved, offer novel treatment options. However, because the company has not yet brought a product to market, any investment thesis depends heavily on future clinical trial results and regulatory milestones. From what I see, this focus on CNS therapies is what keeps the story interesting for those tracking early-stage biotechs.
Key Risks to Consider
Investing in Silo Pharma carries substantial risks typical of development-stage biopharmaceutical companies. The company has reported net losses and has no approved products, meaning its ability to generate meaningful revenue depends on the success of clinical trials that may take years and may ultimately fail.
Key risks include:
- Clinical and regulatory risk: Drug candidates must pass rigorous clinical trials and FDA review, with no guarantee of approval.
- Financing risk: As an early-stage company with minimal revenue, Silo Pharma may need to raise additional capital, which can dilute existing shareholders.
- Competition: The CNS and mental health treatment space is competitive, with larger pharmaceutical companies and other biotechs pursuing similar indications.
- Operational scale: With a very small workforce, the company has limited internal resources relative to larger competitors.
- Psychedelic regulatory complexity: Therapies involving controlled substances such as ketamine and psilocybin face additional legal and regulatory considerations.
Using AI Tools to Expand Research
In my own work, I often turn to Tickeron's AI Screener when I want to place a single name like SILO in broader context. It is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. For those seeking to broaden their research beyond a single ticker, exploring the AI Screener can help uncover additional candidates aligned with a particular investing approach.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SILO saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for SILO moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 46 similar instances where the indicator exited the overbought zone. In 43 of the 46 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SILO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SILO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SILO's RSI Indicator exited the oversold zone, 24 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on SILO as a result. In 93 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
Following a +9.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where SILO advanced for three days, in 213 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
SILO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.466) is normal, around the industry mean (3.498). P/E Ratio (-0.348) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (3.910) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (28.736) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. SILO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SILO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement